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Kevin A. Dahl, BA,a Kemp H. Kernstine, MD, PhD,a Timothy L. Vannatta, MD,a Mark W. Karwal, MD,bKarl W. Thomas, MD,b and Daniel F. Schraith, MD,c Iowa City, IowaAmyloidosis results from abnormal protein depositionand accumulation in extracellular spaces.1 The multi-ple distinct forms of this disease have heterogeneousclinical manifestations and variable patterns of organ
involvement. Amyloidosis might be hereditary or acquired, local-
ized, or systemic and can range from an incidental asymptomatic
finding to a lethal disorder. The diseases are distinguished on a
molecular level by the type of peptide subunits that compose
abnormally accumulated protein fibrils. Although these peptide
fibrils differ, all amyloid fibrils adopt a similar ultrastructure rich
in -sheet content. The fibril deposits also have a common asso-
ciation with certain glycosaminoglycans (GAGs), notably heparin
and dermatan sulphate. Normal plasma proteins, such as serum
amyloid P (SAP), function to stabilize the amyloid fibril.1 We
present a case of severe tracheobronchial amyloidosis (TBA) with
the results of our evaluation and management strategies.
Clinical Summary
A 49-year-old white man had a 6-year history of progressive
dyspnea and productive cough. He had an accelerated symptom
progression over the prior 6 months and also noted the new onset
of intermittent malaise, myalgias, arthralgias, fever, chills, and
night sweats. He had been treated with parenteral and oral antibi-
otics, as well as a variety of inhaled bronchodilators for suspected
pulmonary infections. Because he experienced only transient im-
provement, a combination of prednisone, fluticasone, albuterol,
salmeterol, and ipratropium were added, but these did not improve
his symptoms.
Past medical history was remarkable for recurrent pneumonia
and bronchitis treated empirically. He had a 30 pack-year smoking
history but quit smoking 11 years previously.
Hepatic, renal, and thyroid function test results were all normal,
as were electrolyte levels and hemography results. Pulmonary
function tests were as follows: forced vital capacity, 4.95 L (101%
of predicted value); forced expiratory volume in 1 second, 4.02 L
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The Journal of Thoraci(88% of predicted value); total lung capacity, 7.06 L (97% of
predicted value); residual volume, 2.25 L (82% of predicted val-
ue); and lung diffusion of carbon monoxide, 30.7 (99% of pre-
dicted value). There was no improvement with a bronchodilator.
The results of chest radiographs 1 to 2 years previously were
normal. Chest radiographs on presentation suggested significant
narrowing of the left main bronchus, with no infiltrates or evidence
of congestion. Chest computed tomography (CT; Figure 1) showed
soft tissue calcification of the proximal left lingular and upper lobe
segment bronchus, suggesting a mass, potentially a broncholith.
Bronchoscopy (Figure 2) revealed an edematous left upper lobe
airway with friable mucosa and lesser involvement of the left
carina and left lower lobe bronchial mucosa. The entire left tra-
cheobronchial tree appeared to have narrowing and stenosis, with
the left upper lobe most severe. Bronchoalveolar lavage of the left
upper lobe did not identify any tumor cells. Histologic examination
of the mucosal biopsy specimen revealed fragments of bone and
cartilage, with calcification, degenerated respiratory epithelium,
amorphous debris, and mild acute and chronic inflammation.
These findings were nonspecific but raised the possibility of pul-
monary hematoma, broncholith, or possibly teratoma. No evidence
of carcinoma or granulomatous disease was found in the superfi-
cial endobronchial biopsy specimens. However, these 2 clinical
entities remained in the differential diagnosis.
Considering the patient’s age, smoking history, chest CT find-
ings, and progressive symptoms, a paraneoplastic syndrome could
not be ruled out. The results of bone scanning and head magnetic
resonance imaging were normal. A whole-body positron emission
tomogram was also normal, except for a single focus of left hilar
activity with a standardized uptake value of 3.5. Surgical consul-
tation was obtained, and the possibility of left pneumonectomy
was discussed with the patient and our health care team given the
atypical clinical presentation and the presence of systemic symp-
toms.
Cervical and left anterior mediastinoscopy revealed no meta-
static disease. Exploratory left thoracotomy showed no pleural
process, and the hilum appeared normal. On palpation, however,
there was a deep hilar mass surrounding the left main stem bron-
chus. Hilar dissection exposed associated adenopathy. Biopsy of
the mass and nodes showed inflammation on frozen section. The
fissure was opened, and encountered nodes underwent biopsy,
demonstrating no malignancy. The upper lobe airway was firm and
bone-like. This bronchus was longitudinally incised along its
membranous portion. Intraluminally, very firm inflammation al-
most completely obliterated the entire upper lobe bronchus. The
visualized scarring and bronchial occlusion was so severe and
solid that it was unlikely the patient would benefit from less
invasive airway techniques, such as laser tissue ablation, balloon
bronchoplasty, or stenting. Given the pathology, the patient would
remain at risk for recurrent pneumonias without definitive treat-
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Brief Communicationsment. After significant deliberation, a left upper lobectomy was
performed, leaving the origin of the left upper lobe bronchus open
to allow examination of the left main stem bronchial lumen. The
severely obstructive and circumferential process extended into
Figure 1. Contrast-enhanced chest CT scan just inferior to the
tracheal bifurcation. A soft tissue mass surrounds the left main
stem bronchus, extending into the bronchial lumen.
Figure 2. On bronchoscopy, this is the appearance of the left
upper lobe bronchus. The bronchial subdivisions are edematous
and narrowed.both the left lower lobe and the left main bronchi. It appeared to
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demonstrated calcification but no tumor. The inflammatory process
and obstruction in the left main stem and lower lobe were so severe
that it was believed also to be irreversible. Thus high transection of
the left main stem bronchus was performed, completing a left
pneumonectomy. The postoperative course was uneventful.
The final pathology revealed marked and diffuse expansion of
the bronchial submucosa by amorphous pink material, which was
consistent with amyloid (Figures 3 and 4). Congo red staining
confirmed the presence of amyloid (Figure 5). Areas of osseous
metaplasia were also noted.
Subsequent clinical evaluation included a fat pad aspirate and
bone marrow biopsy, and immunofixation studies of serum and
urine demonstrated no evidence of systemic amyloidosis. Six
months after pneumonectomy, the patient continued to have sys-
temic nonpulmonary symptoms, including malaise, myalgias, ar-
thralgias, and failure to thrive.
Discussion
Amyloid is not a single, molecularly distinct protein; it is more
accurately defined as a group of molecularly diverse proteins
composed of nonbranching linear fibrils arranged in sheets. The
heterogeneity of amyloidosis is attributable in part to the diversity
of fibril precursor peptide units that constitute amyloid. Common
to all amyloid protein is an ultrastructure rich in -sheet content
and structural associations with GAGs. Plasma proteins, notably
SAP, stabilize the long linear amyloid fibrils.1 The majority of
amyloidosis, both systemic and localized types, consist of the light
chain–associated subunit. Other amyloid types also exist and are
composed of a spectrum of precursor peptide units1; a detailed
discussion of the complex biochemistry of amyloid proteins is
beyond the scope of this discussion.
Amyloid deposition can occur in the lung in the setting of
primary or secondary systemic disease or can be limited to the
lung. In primary systemic amyloidosis, amyloid deposits in the
Figure 3. Histologic sample of the bronchus. Normal ciliated
respiratory mucosal lining at the upper left, bronchial cartilage at
the lower left, and submucosa widely distended with amorphous
pink material, amyloid, is shown.lung in 30% to 90% of cases, usually in a diffuse distribution.
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tory diseases, including Crohn disease, ankylosing spondylosis,
tuberculosis, and bronchiectasis. When amyloid deposition is lim-
ited to the respiratory tract, it is usually in one of 3 patterns of
distribution: (1) nodular parenchymal; (2) tracheobronchial; and
(3) diffuse alveolar septal, also called diffuse parenchymal.
TBA is characterized by amyloid deposits primarily in the
trachea and large bronchi, with extension at times into segmental
bronchi. Submucosal vessels are frequently involved.2 TBA typi-
cally presents in patients in their 40s and 50s, with reports ranging
from age 27 to 85 years.1,3 Common presenting symptoms include
chronic cough, dyspnea, wheezing, hemoptysis, and recurrent
pneumonia.1,3 The pulmonary symptomatology help to distinguish
it from other forms of pulmonary amyloidosis because patients
with primary systemic amyloidosis rarely present with pulmonary
symptoms, and the nodular parenchymal form is often an inciden-
tal finding.2 Radiographic findings of TBA include focal or diffuse
airway wall thickening, a localized nodule within the airway
lumen, or possible airway obstruction with atelectasis, postob-
structive pneumonia, and distal lung air trapping.2 Grossly, the
airway appears thickened and irregular, with waxy, firm, or gritty
deposits and yellow, gray, tan, or white coloring.2 TBA has been
confused with tracheobronchopathia osteoplastica, which is char-
acterized by calcified or cartilaginous submucosal nodules but
without amyloid deposition.1 The clinical presentation can be
similar to that of tracheobronchopathia osteoplastica, lymphopro-
liferative disorders, primary or metastatic neoplasms, relapsing
polychondritis (which involves the laryngeal and tracheal car-
tilages in 50% of patients), sarcoidosis, and Wegener granu-
lomatosis.2,3 Lymphoproliferative disorders and neuroendo-
crine tumors, especially carcinoids and small cell carcinomas,
might develop tracheobronchial amyloid deposits, although the
airway amyloid is minimal compared with that seen in primary
Figure 4. Histologic sample of bronchus demonstrating submu-
cosa. Seromucinous glands and blood vessels are entrapped in
the amyloid. With normal ciliated respiratory mucosal lining at
left, osseous metaplasia is present in the center as pink branch-
ing trabeculae. The submucosa is widely distended with amor-
phous pink amyloid.TBA.2
The Journal of ThoraciDiagnosis of TBA requires histologic confirmation; Congo Red
stain highlights the amyloid with a characteristic apple green
birefringence with polarized light.1 Some have advocated immu-
nohistochemical analysis of the amyloid deposits to determine
the fibril type.1 Although the light chain–associated type is
typical in TBA (as well as primary systemic amyloidosis), other
rarer fibril types can be detected and might have therapeutic
implications.4
A comprehensive evaluation, including radiolabeled SAP scan,
CT scan of the thorax, echocardiography, and bone marrow, se-
rum, and urine studies need to be performed to accurately differ-
entiate localized from systemic disease.4 Radiolabeled SAP local-
izes amyloid deposits in proportion to the quantity of amyloid
present, thus assisting diagnosis, quantification, and monitoring of
amyloid deposits. Electrocardiography and echocardiography are
fairly sensitive and specific for cardiac involvement, which com-
monly occurs in systemic amyloidosis and is a major prognostic
determinant.1 Protein electrophoresis studies on serum and urine
can help detect an underlying lymphoproliferative disorder with an
associated monoclonal gammopathy. However, up to 10% of pa-
tients with limited pulmonary amyloidosis might demonstrate cir-
culating monoclonal proteins.2
Although a localized disease process, overall survival in TBA
is only 31% to 43% at 4 to 6 years.2 In contrast, pulmonary
amyloidosis is generally a benign process, with resection being
both diagnostic and curative. Therefore differentiating these 2
entities has profound prognostic implications.2
There is no proved pharmacologic therapy for TBA. Treatment
options include bronchoscopic or surgical resection, as well as
laser therapy.1 Management of TBA is largely dictated by the
degree of symptoms. Treatment might involve intermittent bron-
choscopic or surgical resection, carbon dioxide laser ablation, and
Nd:YAG laser therapy.1 Repeated bronchoscopic treatment is
Figure 5. Congo Red stain of the bronchus histology. Amyloid
demonstrates the characteristic apple green birefringent optical
quality with polarized light.thought to be safer than open surgical intervention.1 However,
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herein. There are anecdotal reports of successful treatment of
pulmonary amyloidosis with dimethylsulfoxide.2 One study re-
ports 2 cases of endobronchial amyloidosis treated with an Nd:
YAG laser, resulting in patency of the involved lung segments 10
and 16 months later.5 External beam radiation therapy has also
been used, with clinical and functional improvement noted after 18
months of follow-up.6
Research is currently underway seeking to prevent amyloid
deposition by stabilizing the amyloid precursor proteins in their
normal conformation, inhibiting fibril propagation, enhancing
fibril degradation, and developing GAG mimetics and SAP bind-
ing inhibitors. Competitive inhibition of SAP binding targets the
stabilizing role of SAP in the amyloid fibril. Pepys and colleagues7
recently reported SAP binding by Ro 63-8695 could both reduce
plasma SAP levels and competitively inhibit SAP-amyloid bind-
ing. The mechanism of action involves cross-linking pairs of
pentameric SAP molecules, thus creating a decameric configura-
tion rapidly cleared by the liver.
TBA is a rare disease resulting from abnormal protein deposi-
tion within the airway submucosa. Despite surgical resection and
treatment of the obstructive pneumonia, long-term survival is poor.
Exclusion of systemic amyloidosis is necessary in the evaluation
792 The Journal of Thoracic and Cardiovascular Surgery ● Noveof a patient with pulmonary amyloid deposition. There is no cure,
although laser therapy, external beam radiation, and pharmaco-
logic SAP binders might potentially improve the outlook for these
patients.
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